ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Novo Nordisk pushes into cell therapy

by Rick Mullin
October 7, 2018 | APPEARED IN VOLUME 96, ISSUE 40

 

Novo Nordisk will sublease a stem cell therapies development facility in Fremont, Calif., from Asterias Biotherapeutics at which it plans to develop treatments for type 1 diabetes and other diseases. The company hopes to be in operation next year. The deal follows Novo Nordisk’s announcement in May of a deal to license technology from the University of California, San Francisco, for creating human embryonic stem cells for regenerative medicines. Novo Nordisk recently established stem cell R&D operations in Måløv, Denmark.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment